Astra profits hit by cheaper rivals

Pharmaceuticals giant AstraZeneca highlighted its battle against cheaper generic drugs today as it posted a 14% drop in third quarter profits.

The UK’s second largest drugs maker reported that US sales of two of its major treatments were under pressure from rivals and it also revealed another of its top-selling treatments was under threat from potential competition.